MiMedx GroupMDXG -1.20%53 Receivables Turnover is 0.97 as of Mar. 2026. GuruFocus rates MDXG with a GF Score™ of 53/100 and a GF Value™ of $6.83 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 840 Biotechnology companies, MiMedx Group ranks better than 55.36% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. MiMedx Group's Revenue for the
three
months ended in Mar. 2026 was $59.0 Mil. MiMedx Group's average Accounts Receivable for the
three
months ended in Mar. 2026 was $60.9 Mil.
Hence, MiMedx Group's Receivables Turnover for the
three
months ended in Mar. 2026 was 0.97.
MiMedx Group (NAS:MDXG) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
MiMedx Group Receivables Turnover Related Terms
MiMedx Group Receivables Turnover Historical Data
* Premium members only.
The historical data trend for MiMedx Group's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MDXG vs MNPR, FTH, BBOT: Receivables Turnover Comparison
For the Biotechnology subindustry, MiMedx Group's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MiMedx Group Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MiMedx Group's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where MiMedx Group's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MiMedx Group (MDXG) has a Receivables Turnover of 0.97 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on MiMedx Group and its competitors. According to the industry distribution chart, MiMedx Group ranks #375 out of 840 companies in the Biotechnology industry, placing it in the top 44.6%.
Is MiMedx Group's Receivables Turnover too high?
MiMedx Group's current Receivables Turnover is 0.97. The Biotechnology industry median Receivables Turnover is 5.30. MiMedx Group's value of 0.97 is 81.7% below this industry median. Based on the distribution chart, MiMedx Group ranks #375 out of 840 companies in the Biotechnology industry, which is above the industry midpoint. Overall, MiMedx Group has a GF Score™ of 53/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does MiMedx Group's Receivables Turnover compare to MNPR and FTH?
According to the Biotechnology industry distribution chart, MiMedx Group ranks #375 out of 840 companies for Receivables Turnover. This puts MiMedx Group in the upper half of its industry. The industry median Receivables Turnover is 5.30. MiMedx Group's value of 0.97 is 81.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.30, based on 840 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MiMedx Group's current Receivables Turnover of 0.97 is 81.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on MiMedx Group and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MiMedx Group's current Receivables Turnover is 0.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MiMedx Group stock overvalued right now?
Based on GuruFocus' analysis, MiMedx Group (MDXG) is currently considered Significantly Undervalued. The stock's GF Value™ is $6.83, compared to a current price of $4.11 — trading 39.8% below its estimated fair value. The current Receivables Turnover is 0.97 and 81.7% below the Biotechnology industry median of 5.30. MiMedx Group's overall GF Score™ is 53/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For MiMedx Group (MDXG), the current Receivables Turnover is 0.97 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MiMedx Group (MDXG) Overvalued in 2026?
Based on GuruFocus' analysis, MiMedx Group stock appears to be undervalued.
The current stock price of $4.11 is trading 39.8% below its estimated GF Value™ of $6.83.
GuruFocus considers MiMedx Group to be Significantly Undervalued.
Key valuation signals for MDXG:
Receivables Turnover: 0.97
GF Value™: $6.83 vs. price of $4.11 (39.8% below fair value)
Industry Position: 81.7% below the Biotechnology median (#375 of 840)
No single metric tells the full story. See the MDXG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, the company sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
53GF Score
Get the complete analysis for MDXG
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MDXG has been successfully added to your 
